Low-Dose Oral Interferon-α
Primary Sjogren’s Syndrome
Key Facts
About Ainos
Ainos is executing a strategic transformation from a legacy interferon developer into a diversified medtech company centered on AI-driven diagnostics. Its core achievement is the development of a proprietary 'AI Nose' platform, which uses MEMS sensor arrays and AI algorithms to analyze volatile organic compounds (VOCs) for non-invasive, point-of-care testing, with initial commercial products for COVID-19 and pneumonia. The strategy leverages nearly four decades of clinical experience and over 60 patents across three divisions: Pharmaceuticals (low-dose interferon), Medical Devices (AI diagnostics), and Preventive Medicine (synthetic RNA), aiming to address unmet needs in infectious disease, women's health, and chronic conditions.
View full company profileAbout Ainos
Ainos is executing a strategic transformation from a legacy interferon developer into a diversified medtech company centered on AI-driven diagnostics. Its core achievement is the development of a proprietary 'AI Nose' platform, which uses MEMS sensor arrays and AI algorithms to analyze volatile organic compounds (VOCs) for non-invasive, point-of-care testing, with initial commercial products for COVID-19 and pneumonia. The strategy leverages nearly four decades of clinical experience and over 60 patents across three divisions: Pharmaceuticals (low-dose interferon), Medical Devices (AI diagnostics), and Preventive Medicine (synthetic RNA), aiming to address unmet needs in infectious disease, women's health, and chronic conditions.
View full company profileAbout Ainos
Ainos is executing a strategic transformation from a legacy interferon developer into a diversified medtech company centered on AI-driven diagnostics. Its core achievement is the development of a proprietary 'AI Nose' platform, which uses MEMS sensor arrays and AI algorithms to analyze volatile organic compounds (VOCs) for non-invasive, point-of-care testing, with initial commercial products for COVID-19 and pneumonia. The strategy leverages nearly four decades of clinical experience and over 60 patents across three divisions: Pharmaceuticals (low-dose interferon), Medical Devices (AI diagnostics), and Preventive Medicine (synthetic RNA), aiming to address unmet needs in infectious disease, women's health, and chronic conditions.
View full company profileAbout Ainos
Ainos is executing a strategic transformation from a legacy interferon developer into a diversified medtech company centered on AI-driven diagnostics. Its core achievement is the development of a proprietary 'AI Nose' platform, which uses MEMS sensor arrays and AI algorithms to analyze volatile organic compounds (VOCs) for non-invasive, point-of-care testing, with initial commercial products for COVID-19 and pneumonia. The strategy leverages nearly four decades of clinical experience and over 60 patents across three divisions: Pharmaceuticals (low-dose interferon), Medical Devices (AI diagnostics), and Preventive Medicine (synthetic RNA), aiming to address unmet needs in infectious disease, women's health, and chronic conditions.
View full company profile